Status:
COMPLETED
Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C
Lead Sponsor:
University of Ulm
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Liver Diseases
Eligibility:
MALE
18-65 years
Phase:
PHASE4
Brief Summary
One single study has suggested that bone mineral density (BMD) is reduced in patients with non-cirrhotic chronic viral hepatitis C. Antiviral combination therapy with standard interferon and ribavirin...
Eligibility Criteria
Inclusion
- proven chronic hepatitis C
- aged between 18 and 65
- male patients
Exclusion
- high grade liver fibrosis (Grade 3 - 4)
- renal disease
- hyperparathyroidism
- hypogonadism
- malignant disease
- use of any other drug known to effect bone mineral metabolism
- use of alcohol
- organ transplant
- any form of thyroid disease
- any medical condition known to be associated with bone loss
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00948220
Start Date
July 1 2003
End Date
March 1 2008
Last Update
June 7 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Ulm
Ulm, Germany, 89081